-
Join 674 other subscribers
-
Recent Posts
- Board IPR decisions finding conception and reduction to practice before critical date affirmed
- SCOTUS concludes Amgen’s anti-PCSK9 antibody claims not enabled
- Board IPR claim construction (even with harmless error) and obviousness determination affirmed
- DC findings that Vanda’s method of treatment claims are invalid for obviousness affirmed
- IPR obviousness decision reversed as prior art not shown to be analogous to Sanofi’s claimed invention
Recent Comments
Categories
- America Invents Act
- Analgous Art
- Anticipation (35 USC 102)
- Antitrust
- Appeal
- Arbitration
- Article III disputes
- Assignment / Ownership
- Attorney's Fees
- Bankruptcy
- Best mode
- Biosimilars
- Business methods
- Certificate of Correction
- Claim
- Claim Construction
- Claim Differentiation
- Claim Preclusion
- Claim Vitiation
- Collateral estoppel
- comprising
- Conception and Reduction to Practice
- consisting of
- Contributory Infringement
- Copyright
- Covered Business Method Reviews
- Damages
- Derivation of Invention
- Design Patents
- Diligence
- Disclaimers
- Discovery
- Doctrine of equivalents
- Double Patenting
- Enablement
- Equitable estoppel
- Exhaustion and Repair
- Experimental Use
- Expert Testimony
- Extension (156)
- False Marking
- Functional limitations
- Generics / ANDA
- Importation
- Incorporation by Reference
- Indefiniteness
- Inducement to Infringe
- Inequitable Conduct
- Infringement
- Inherency
- Injunction
- Inter Parties Review (IPR)
- Interference
- International Trade Commission
- Intervening Rights
- Inventorship
- IPR
- Issue Preclusion
- Jurisdiction
- Laches
- Licensing
- Lost Profits
- Malpractice
- Markush
- Means-plus-function
- Medical Devices
- Method claims
- Negative Limitations
- Obviousness
- Obviousness (Secondary Considerations)
- Obviousness-Teaching Away
- On-Sale Bar
- Patent Eligibility (101)
- Patent Exhaustion
- Patent Marking
- Patent Prosecution
- Patent Term Adjustment (PTA)
- Patent Term Extension
- Patentability
- Post-grant review
- Preamble
- Priority
- Privilege
- Procedural Issues
- Product-by-Process
- Prosecution History Estoppel
- Public Accessibility
- Public Use
- Ranges
- Reexamination
- Reissue
- Royalties
- Safe Harbor, FDA exemptions (271(e)(1))
- Section 101 (see also Patentability)
- Software
- State Sovereignty
- Summary Judgment
- Terminal Disclaimers
- Trade Dress
- Trade Secret
- Trademarks
- U.S. Supreme Court
- Uncategorized
- Unenforceability
- Unjust enrichment
- Utility
- Venue
- Wherein
- Willfullness
- Written description
Archives
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- July 2011
- February 2011
- January 2011
Meta
- Anticipation (35 USC 102) Appeal Article III disputes Assignment / Ownership Attorney's Fees Claim Construction Claim Differentiation Damages Doctrine of equivalents Enablement Generics / ANDA Indefiniteness Inducement to Infringe Infringement Inter Parties Review (IPR) Inventorship IPR Licensing Means-plus-function Obviousness Obviousness-Teaching Away Patentability Patent Eligibility (101) Prosecution History Estoppel Reexamination Software Trademarks Uncategorized Willfullness Written description
Copyright Notice
© Patrick J. Halloran, Ph.D., J.D. and lifescienceip.wordpress.com, [2011-2017]. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Patrick J. Halloran, Ph.D., J.D. and lifescienceip.wordpress.com with appropriate and specific direction to the original content.
Monthly Archives: November 2017
PTO issues “Guidance on Motions to Amend in view of Aqua Products”
PTO Guidance on Motions to Amend in view of Aqua Products Update following Oct. 4, 2017 FC (en banc) opinion (Aqua Products, Inc. v. Joseph Matal (USPTO), Docket No. 2015-1177 (IPR2013-00159): USPTO issued guidance on Nov. 21, 2017, explaining that … Continue reading
Posted in Inter Parties Review (IPR), IPR
Leave a comment
Rembrandt Patent Innovations, LLC et al. v. Apple, Inc.
Docket No. 2016-2324 PROST, CHEN, HUGHES November 22, 2017 Non-precedential Brief summary: DC claim construction and finding of no infringement by Apple affirmed. Summary: Rembrandt appealed DC grant of SJ of noninfringement by Apple’s “mobile products” (iPhone, iPad, and iTouch) … Continue reading
Eli Lilly et al. v. Perrigo / Amneal
Docket No. 2016-2555, -2614 CHEN, PLAGER, HUGHES November 22, 2017 Non-precedential Brief summary: DC decision that certain claims are not obvious (e.g., the prior art does not teach away); that certain other claims are obvious (e.g., alternatives theories presented here … Continue reading
Posted in Infringement, Obviousness
Leave a comment
Presidio Components, Inc. v. American Technical Ceramics Corp.
Docket No. 2016-2607, -2650 DYK, MOORE, TARANTO November 21, 2017 Brief summary: DC conclusion of no indefiniteness, that “ATC was entitled to the defense of absolute intervening rights”, and denial of enhanced damages affirmed. Award of lost profits and permanent … Continue reading
Posted in Damages, Indefiniteness, Injunction, Lost Profits
Leave a comment
BASF Corporation v. Johnson Matthey, Inc.
Docket No. 2016-1770 LOURIE, O’MALLEY, TARANTO November 20, 2017 Brief summary: DC finding of indefiniteness reversed and remanded (e.g., no “context-specific inquiry into whether particular functional language actually provides the required reasonable certainty”). Summary: BASF appealed the “effective for catalyzing”/“effective … Continue reading
Posted in Indefiniteness
Leave a comment
Mexichema Amanco Holding v. Honeywell International
Docket No. 2016-2084, -2085, 2017-1050 PROST, DYK, CHEN November 17, 2017 Non-precedential Brief summary: PTAB decisions reversing Examiner’s definition of “azeotrope-like” affirmed as the term is explicitly defined by the specifications and the Examiner’s definition would have read the term … Continue reading
Posted in Claim Construction
Leave a comment
In re: Micron Technology, Inc.
Docket No. 2017-138 TARANTO, CHEN, HUGHES November 15, 2017 Brief summary: DC denial of Micron’s TC Heartland-based venue objection under FCRP 12(h)(1)(A) vacated and remanded for consideration under the “less bright-line more discretionary framework” of Dietz (US 2016). Summary: Micron … Continue reading
Posted in Venue
Leave a comment
Amgen Inc. et al. v. Apotex Inc. et al.
Docket No. 2017-1010 LOURIE, O’MALLEY, TARANTO November 13, 2017 Non-precedential Brief summary: DC decision of no infringement of Amgen’s process patent by Apotex’s ABLA applications regarding Amgen’s Neulasta® and Neupogen® affirmed. Summary: Amgen appealed DC conclusion that Amgen failed to … Continue reading
Posted in Biosimilars, Generics / ANDA, Infringement
Leave a comment
Promega Corporation et al. v. Life Technologies Corporation et al.
Docket No. 2013-1011, -1029, -1376 PROST, MAYER, CHEN November 13, 2017 Brief summary: DC grant of Life’s motion for JMOL that Promega failed to prove infringement under § 271(a) and (f)(1), and its “vacatur of the [DC’s] denial of Promega’s … Continue reading
Posted in Damages, Lost Profits, Royalties
Leave a comment
Sanofi, et al. v. Watson Laboratories, Sandoz Inc.
Docket No. 2016-2722, -2726 PROST, WALLACH, TARANTO November 9, 2017 Brief summary: DC decision finding inducement to infringe based on proposed drug label, no obviousness in view of prior art clinical trial documents, or prosecution history estoppel affirmed. Summary: Sanofi … Continue reading
Federal Circuit summaries 